In the BioFINDER cohort (Table 1), we included 338 biomarker-positive (defined by an elevated CSF Aβ42/P-tau ratio, representing 55.8% of 605 eligible participants in the study) participants classified as having SCD (n = 54), MCI (n = 150), or AD (n = 134). Here, MAPT is linked to Alzheimer disease.